motexafin gadolinium

Motexafin gadolinium (PCI 0120) is a potent antitumor agent. Motexafin gadolinium is a specific texaphyrin in complex with gadolinium(III). Motexafin gadolinium increases intracellular ROS production. Motexafin gadolinium enhances sensitivity of tumor cells to ionizing radiation[1][2][3].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Motexafin gadolinium (50 µM; 22 h) 导致 A549 细胞中的二氯荧光素乙酸盐 (DCFA) 氧化[1]。 Motexafin gadolinium (100 µM；4、12 小时) 与 Zn (100 μM) 和抗坏血酸 (100 μM) 结合时，可增加拉莫斯淋巴瘤细胞中细胞内 ROS 的产生和细胞凋亡 (24 小时)[2] . 当与锌 (100 μM) 和抗坏血酸 (100 μM) 结合使用时，Motexafin gadolinium (0.01-100 μM) 会剂量依赖性地降低 HF-1 细胞中 p53 蛋白的表达[2]。 Western Blot Analysis[2] Cell Line: HF-1 cells Concentration: 0.01-100 μM, with Zn (100 μM), and ascorbate (100 μM) Incubation Time: 5 h Result: Elicited a dose-dependent decrease in p53 in HF-1 cells, does not reduce p53 message in Ramos cells.

[1]. Magda D, et al. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 2006 Dec;16(6):466-76.  

[2]. Singh AT, et al. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. Anticancer Res. 2010 Apr;30(4):1131-6.  

[3]. Evens AM, et al. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res. 2009 Oct 15;15(20):6462-71.